@article{c770063b3d76421cbdae8ea52904ec10,
title = "Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians",
abstract = "Dual antiplatelet therapy with aspirin and a thienopyridine has been shown to reduce cardiac events after coronary stenting. However, many patients and healthcare providers prematurely discontinue dual antiplatelet therapy, which greatly increases the risk of stent thrombosis, myocardial infarction, and death. This advisory stresses the importance of 12 months of dual antiplatelet therapy after placement of a drug-eluting stent and educating the patient and healthcare providers about hazards of premature discontinuation. It also recommends postponing elective surgery for 1 year, and if surgery cannot be deferred, considering the continuation of aspirin during the perioperative period in high-risk patients with drug-eluting stents.",
keywords = "AHA Scientific Statements, Myocardial infarction, Myocardial stunning, Stents, Thrombosis",
author = "Grines, {Cindy L.} and Bonow, {Robert O.} and Casey, {Donald E.} and Gardner, {Timothy J.} and Lockhart, {Peter B.} and Moliterno, {David J.} and Patrick O'Gara and Patrick Whitlow",
note = "Funding Information: Writing Group Disclosures Writing Group Member Organization Represented Employment Research Grant Other Research Support Speakers' Bureau/ Honoraria Ownership Interest Consultant/ Advisory Board Other Cindy L. Grines AHA Representative William Beaumont Hospital None None None None None None Robert O. Bonow AHA Representative Northwestern University None None None None None None Donald E. Casey, Jr ACP Representative Atlantic Health None None None None None None Timothy J. Gardner ACS Representative Christiana Care Health System None None None None None None Peter B. Lockhart ADA Representative Carolinas Medical Center None None None None None None David J. Moliterno SCAI Representative University of Kentucky None None None None None None Patrick O'Gara ACC Representative Brigham and Women's Hospital None None None None None None Patrick Whitlow ACC Representative Cleveland Clinic None None None None ICON Interventional Systems, ⁎ Medlogics ⁎ None AHA indicates American Heart Association; ACP, American College of Physicians; ACS, American College of Surgeons; ADA, American Dental Association; SCAI, Society for Cardiovascular Angiography and Interventions; and ACC, American College of Cardiology. This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12-month period or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition. ⁎ Modest. Reviewer Disclosures Reviewer Employment Research Grant Other Research Support Speakers' Bureau/ Honoraria Expert Witness Ownership Interest Consultant/ Advisory Board Other Elliott M. Antman Brigham and Women's Hospital Eli Lilly ⁎ None None None None None None Gregory J. Dehmer Texas A&M University College of Medicine and Scott & White Clinic None None None None None None None T. Bruce Ferguson East Carolina University None None None None None None None Raymond J. Gibbons Mayo Clinic Radiant Medical, † KAI Pharmaceuticals, † TargeGen, † TherOx † None None None None Hawaii Biotech, ⁎ TIMI 37A ⁎ None Arthur H. Jeske University of Texas Health Science Center, Houston None None None None None None None Vincenza Snow American College of Physicians None None None None None None None This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12-month period or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition. ⁎ Modest. † Significant. ",
year = "2007",
month = feb,
doi = "10.1161/CIRCULATIONAHA.106.180944",
language = "English (US)",
volume = "115",
pages = "813--818",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6",
}